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Introduction
The intracellular enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a monomeric oxidoreductase that catalyses the first and rate-limiting step in tryptophan degradation, leading to subsequent production of bioactive tryptophan metabolites kynurenine (Sono and Hayaishi, 1980; Botting, 1995; Sono et al., 1996) . IDO1 has been proposed as a potential contributor to immunosuppression, tolerance and tumour escape from the immune system (Munn et al., 1999; Mellor, 2004, 2007; Prendergast, 2008) . IDO1-mediated depletion of tryptophan and production of kynurenine can lead to an immunosuppressive tumour micro-environment (TME), in which the proliferation of effector T cells is inhibited while suppressive populations of regulatory T cells are activated (Fallarino et al., 2002; Frumento et al., 2002; Mellor, 2004, 2007) . The presence of IDO1 in TME has been shown to correlate with tumour progression, invasion and metastasis and can be used as an independent prognostic marker of survival in various types of cancers (Brandacher et al., 2006; Polak et al., 2007; Ino et al., 2008; Pan et al., 2008) . It has been demonstrated that IDO1 is produced mainly by the tumour cells and host-derived immune cells such as dendritic cells (DCs) and macrophages that are recruited to TME by the tumour (Munn et al., 1999; Munn et al., 2002) .
The TME is the cellular micro-environment in which the tumour exists, which includes tumour-infiltrating immune cells (e.g. T cells, DCs and macrophages) and non-haematopoietic stromal cells such as cancer-associated fibroblasts (CAFs), endothelial cells (ECs) and pericytes, along with the extracellular matrix (ECM) and inflammatory mediators they secrete (Coussen and Werb, 2002; Johansson et al., 2008; Hanahan and Weinberg, 2011; Hanahan and Coussens, 2012; Turley et al., 2015) . There is emerging evidence suggesting that the crosstalk (interaction) between the stromal compartment and immune system within the TME can influence tumour growth, metastasis and chemoresistance (Joyce and Pollard, 2009; Holmgaard et al., 2013) . CAFs, the predominant stromal cells, together with ECs and pericytes, enhance the proliferation, extravasation and infiltration of regulatory T cells and reduce the trafficking of proliferative effector T cells to the tumour bed, which can hinder antitumour immune responses and promote tumour progression (Castermans and Griffioen, 2007; Buckanovich et al., 2008; Tan et al., 2011; Feig et al., 2013; Turley et al., 2015) . ECM, the non-cellular component in the TME, may also suppress antitumour immune responses and thus support tumour growth by limiting T cell motility (Provenzano et al., 2012; Salmon et al., 2012; Caruana et al., 2015; Turley et al., 2015) . However, the stromal immunoregulation in the TME is not unidirectional. A growing body of evidence now exists to suggest that the infiltrating immune cells can actively shape the stromal milieu in the TME, thus highlighting a considerable level of crosstalk (interaction) between stromal and immune cells (Beatty et al., 2011; Lu et al., 2011; Coussens et al., 2013; Turley et al., 2015) . Stromal cells and their associated ECM are now known to play an essential role in controlling the expansion of cancer stem cells (CSCs), a population of tumour cells that possess the defining features of clonogenicity and self-renewal, and CSCs are thought to have a critical role in tumour progression, metastasis and chemoresistance (Bhowmich et al., 2004; Turley et al., 2015; Ni et al., 2016) .
It is still unclear whether tumour cell-derived IDO1 contributes to tumour progression in patients (Holmgaard et al., 2013) . In the present study, we perform a bioinformatic analysis of the relationship between tumour cell-derived IDO1 expression levels and survival rates in patients using an online tool (http://kmplot.com/analysis/), which is capable of assessing the effect of 54 675 genes on survival using 10 461 cancer samples, including 5143 breast, 1816 ovarian, 2437 lung and 1065 gastric cancer patients with a mean followup of 69, 40, 49 and 33 months respectively (Gyorffy et al., 2010 (Gyorffy et al., , 2012 (Gyorffy et al., , 2013 Szasz et al., 2016) .
IDO1 is emerging as an important new therapeutic target for the treatment of cancer, and three small-molecule inhibitors of IDO1, 1-methyl-tryptophan (1-MT), NLG919 and epacadostat are currently in clinical trials for treatment of non-small cell lung cancer (NSCLC), melanoma and other types of cancer (Cady and Sono, 1991; Liu et al., 2010; Jackson et al., 2013) . However, the antitumour efficacy of these existing inhibitors is still unsatisfactory and the underlying mechanism remains largely undefined. In the present study, we describe the discovery and characterization of LW106, a structurally novel small-molecule inhibitor of IDO1. We found that LW106 displays a stronger antitumour efficacy as compared with epacadostat, and further revealed that LW106 inhibits tumour growth by limiting the interaction (crosstalk) between the stromal compartment and the immune system and the enrichment of CSCs in the TME. Our data suggest that LW106 can be further developed as a potential immunotherapeutic agent for cancer treatment.
Methods

Mice and human samples
Eight-week-old male C57BL/6 mice and athymic nude mice were purchased from Qinglongshan Animal Facility in Nanjing, China. Congenic Ido1 À/À mice on a C57BL/6 strain background were obtained from the Jackson Laboratory. All mice were housed under standard specific-pathogen-free conditions, and all research involving animals strictly complied with protocols approved by the Animal Welfare and Ethics Committee (China Pharmaceutical University). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Human peripheral blood mononuclear cells (PBMCs) from healthy volunteers were purchased from Nanjing Red Cross Blood Centre.
Cell culture
HeLa ovarian carcinoma cells, Lewis lung carcinoma cells and B16F10 melanoma cells were purchased from ATCC (Rockefeller, MD, USA) and grown in DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Cells were tested for mycoplasma contamination each month, and only mycoplasmanegative cells were used. Short tandem repeat DNA fingerprinting analysis was performed in 2016 for authentication of these cells.
Tumour formation and drug treatment
Tumour xenograft experiments were performed in 8-to 10-week-old mice challenged s.c. with 6 × 10 5 Lewis tumour cells or 2 × 10 5 B16F10 melanoma cells. Mice were randomly divided into five groups and injected i.p. daily with vehicle alone, LW106 at doses of 20, 40 and 80 mg·kg À1 or epacadostat at 80 mg·kg À1 at day 6 following initial tumour cell engraftment until termination of the experiment. All compounds were dissolved freshly in sodium citrate buffer prior to each experiment. Tumour volume was measured every 2 days at day 3 post-tumour inoculation using the formula V = π × length × width 2 /6. Tumours were harvested, weighed and subjected to further analysis.
FACS analysis
For the T cell assay, xenografted tumours were dissected, minced into small pieces and digested for 45 min at 37°C in 1X HBSS buffer containing 2% FBS, 1 mg·mL À1 collagenase I (Sigma-Aldrich, St Louis, Missouri, USA) and 0.5 mg·mL À1 dispase (Invitrogen), followed by further digestion in 10-μg·mL À1 DNase (Invitrogen) for 45 min, and 0.64% ammonium chloride (STEMCELL Technologies, Vancouver, Canada) for 5 min at 37°C; Spleens from tumour-bearing mice were dissected into pieces and dissociated mechanically in D-Hank's buffer (Invitrogen) for 10 min on ice. Cells were filtered through a 70 μm cell strainer (BD Biosciences, Franklin Lakes, NJ, USA), resuspended in 1X HBSS buffer containing 2% FBS and subjected to a gradient centrifugation in Ficoll-Pague (Sigma-Aldrich). Purified lymphocytes were stained using a fixation and permeabilization kit (eBioscience, San Diego, CA, USA) and analysed by FACS analysis to detect the expression of CD45, CD4, CD8, Foxp3 (all from Biolegend, San Diego, CA, USA) and Ki67 (Cell Signaling, Danvers, MA, USA). For the CSC assay, xenografted tumours were dissected into pieces and dissociated enzymatically as described above. Cells were incubated with an antibody cocktail containing CD31, CD45 and Ter119 (STEMCELL Technologies), a secondary biotin-labelled antibody cocktail (STEMCELL Technologies) and magnetic beads (15 min each). The unbound cells (LIN À ) were collected and labelled with APC-CD44 or PE-CD144 (both from BD Biosciences) for 30 min at 4°C, followed by DAPI staining for 5 min at 4°C. Cells were washed extensively and subjected to an aldehyde dehydrogenase (ALDH) activity assay using a kit from STEMCELL Technologies, according to the manufacturer's instructions. The labelled cells were subjected to FACS analysis to detect ALDH activity and the expression of CD133 and CD44.
Lymphocyte and DC co-culture
Lymphocyte and DC co-cultures were performed as described previously with a slight modification (Liu et al., 2010) . PBMCs from healthy volunteers were subjected to centrifugal elutriation to obtain monocytes and lymphocytes. The purified monocytes were treated with 10 ng·mL À1 human recombinant 
Tryptophan/kynurenine measurement
Tryptophan/kynurenine measurements were performed as described previously with slight modifications (Liu et al., 2010) . To measure IDO1 enzyme activity in vitro, HeLa cells were stimulated with 50 ng·mL À1 human recombinant IFN-γ for 48 h, and conditioned media were collected, centrifuged to remove cell debris and stored at À20°C for further use. To measure IDO1 enzyme activity in vivo, blood and tumours from vehicle-or drug-treated mice were collected and stored at À20°C for further use. Tumours were homogenized in three volumes of normal saline with 0.1% formic acid. Following protein-precipitation extraction with methanol, supernatants of conditioned media, plasma and tumour homogenates were collected and 20 μL of the supernatants were subjected to LC/MS/MS analysis. Aqueous standards were prepared for adjustment of endogenous tryptophan and kynurenine levels.
Histological and immunohistochemical analyses
For histology, tissues were fixed in 4% paraformaldehyde, embedded in paraffin and sectioned, followed by haematoxylin and eosin (H&E) staining. For immunohistochemical assays, paraffin-embedded sections were deparaffinized, rehydrated and subjected to antigen heat retrieval with citric buffer, pH 6.0 (Vector Laboratories, Burlingame, CA, USA). The sections were treated with 0.5% H 2 O 2 (Sigma-Aldrich) for 10 min at room temperature and further incubated in blocking buffer (5% goat serum in PBS) supplemented with primary antibodies against cleaved caspase 3 (Cell Signaling), Ki67 (Abcam, Cambridge, UK) and p-Histone H3 (Cell Signaling) overnight at 4°C, followed by incubation with biotinylated goat anti-rabbit secondary antibody (Vector Laboratories) at room temperature for 1 h. A standard ABC kit and DAB (Vector Laboratories) were used for the detection of HRP activity. Sections were counterstained with haematoxylin, dehydrated and mounted. In some experiments, sections were incubated in blocking buffer (5% goat serum in PBS) containing primary antibodies against CD31, α-smooth muscle actin (α-SMA) (both from Abcam), K14 (Biolegend) and CD8 (Biolegend) overnight at 4°C, followed by incubation with goat anti-rat Alexa 488, goat anti-rabbit Alexa 488 and goat anti-rabbit Alexa 594 secondary antibodies (all from Invitrogen) for 1 h at room temperature. Sections were stained with DAPI for 5-10 min at room temperature and mounted for confocal microscopy.
Immunoblotting assay
Cells were harvested and lysed in RIPA buffer (Thermo Scientific) containing proteinase inhibitor cocktail (Thermo Scientific) on ice for 20 min, followed by centrifugation for 20 min at 4°C, 14 000 g. The supernatants were collected and subjected to immunoblotting assay using anti-IDO1 antibody (Merck).
Cell survival assay
Tumour cells were seeded in 12-well culture plates and treated with vehicle or the indicated compounds at different concentrations for 2 days. Cells were harvested, resuspended in trypan blue staining buffer (containing 0.04% trypan blue, Thermo Fisher) and cultured for 3 min at room temperature. Live cells (i.e. cells that excluded trypan blue) were instantly counted under light microscope, and survival rates of cells were calculated.
Kaplan-Meier survival analysis
Overall survival (OS), post-progression survival (PPS) and distant-metastasis-free survival (DMFS) rates were assessed in lung cancer patients (with indicated subtypes; Gyorffy et al., 2010) , ovarian cancer patients (Gyorffy et al., 2012) , breast cancer patients (Gyorffy et al., 2013) and gastric cancer patients (Szasz et al., 2016) . The patients were divided into 'high' and 'low' groups by median IDO1 expression. All other parameters were left as default settings.
Statistical analysis
All results wherever necessary were subjected to statistical analysis. Data are presented as mean ± SEM. Statistical analysis was performed as described in each corresponding figure legend. Sample sizes are shown in each corresponding figure legend. P < 0.05 was considered significant. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Chemical compounds
LW106 (MW: 245; Figure S1 ) was synthesized at the Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, and the purity was no less than 99%. Using the binding model of the lead compound 62 with IDO1 (PDB code: 2D0T) by molecular docking, we probed the active site and discovered more potent IDO inhibitors based on 62. It was observed oximido of 62 could interact with haem 7-propionic acid to form a conserved hydrogen contributing greatly to the strong protein occupancy. 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
Tumour cell-derived IDO1 expression level does not correlate with cancer patient survival
To date, it is still controversial whether tumour cell-derived IDO1 expression level correlates with cancer patient survival (Holmgaard et al., 2013) . Using a Kaplan-Meier survival analysis (http://kmplot.com/analysis/), we failed to observe a statistically significant relationship between OS, PPS and DMFS rates and tumour cell-derived IDO1 expression level in patients with various types of cancers such as lung, ovarian, breast or gastric cancer (Figure 1A -H; Figure S2A -D). These data suggest that targeting IDO1 as a therapeutic strategy might be applicable to IDO1-expressing host-derived cells but not tumour cells.
LW106 inhibited IDO1 enzyme activity but did not affect tumour cell proliferation in vitro
To determine the in vitro inhibitory effect of LW106 on IDO1 enzyme activity, HeLa ovarian carcinoma cells were stimulated with IFN-γ and applied to an enzyme activity assay. It has been reported that expression level of IDO1 but not IDO2 or tryptophan 2,3-dioxygenase (TDO2) was dramatically increased in the stimulated cells (Liu et al., 2010) . We observed that LW106 inhibited IDO1 enzyme activity with an IC 50 value of 1.57 μM while did not affect IDO1 protein expression level in the stimulated cells ( Figure S3A, B) . Moreover, LW106 at doses ranging from 12.5 to 200 μM did not affect proliferation of three types of tumour cells with different expression levels of IDO1 ( Figure S3C -E). It has been reported that IDO1 + DCs can inhibit T-cell proliferation/survival, which is believed to be responsible for IDO1-mediated tumour escape (Mellor et al., 2003) . To examine whether LW106 could reverse IDO1-mediated T-cell suppression, IDO1 + mature DCs or IDO1 À immature DCs were co-cultured with purified lymphocytes in the presence of vehicle, LW106 or epacadostat. Co-cultured cells were harvested, stained with anti-CD8 antibody and subjected to FACS analysis. We found that IDO1 induction strongly suppressed CD8 + T-cell proliferation/survival in the co-culture system, and the suppression could be effectively reversed by LW106 and epacadostat ( Figure S4A, B (Figure 2A ). Importantly, we failed to observe pathological changes in vital organs (e.g. heart, liver, lung and kidney) of mice that received LW106 treatment at 80 mg·kg À1 ( Figure S3A ). Meanwhile, epacadostat treatment at 80 mg·kg À1 reduced tumour weight by 51%, displaying a weaker antitumour efficacy as compared with LW106 ( Figure 2A ). Similarly, a significant reduction in tumour volumes was observed in LW106-treated mice relative to vehicle-treated mice ( Figure 2B ). A marked reduction in kynurenine/tryptophan ratio was also detected in plasmas and xenografts of LW106-treated mice ( Figure 2C ). However, it should be noted that tryptophan depletion and GCN2 kinase activation may also play important roles in IDO1-mediated tumour immune escape (Munn et al., 2005; Eleftheriadis et al., 2014) . Of note, both LW106-and epacadostat-treated mice displayed markedly increased survival compared with vehicle-treated mice ( Figure 2D ). It has been documented that IDO1 enzyme inhibitors require intact T-cell function to suppress tumour growth in mice (Liu et al., 2010) . To evaluate the importance of T-celldependent immunity to the antitumour effect of LW106, athymic nude mice that are deficient in mature T cells were challenged with Lewis tumour cells and tumour outgrowth were monitored. In the context of these mice, LW106 treatment at 80 mg·kg À1 had no distinguished effect on tumour outgrowth, suggesting that LW106 exerts its antitumour effect in a T-cell-dependent manner ( Figure 2E ). We further applied Ido1 À/À (Ido1 knockout) mouse model to determine whether IDO1 blockade in the inoculated tumour cells or the host-derived cells is directly relevant to the mechanism of antitumour effect of LW106. Interestingly, we found that LW106 treatment at 80 mg·kg À1 failed to suppress tumour outgrowth in Ido1 À/À mice that were inoculated with IDO1-expressing Lewis tumours, suggesting that LW106 inhibited tumour outgrowth via blocking activity of IDO1 expressed by the host-derived cells but not the inoculated tumour cells ( Figure 2F ). Figure 3A) . We did not observe pathological changes in vital organs (e.g. heart, liver, lung and kidney) of mice that received LW106 treatment at 80 mg·kg À1 ( Figure S5A, B) . Epacadostat displayed a weaker antitumour efficacy than LW106, with a 50% reduction in tumour weight when administrated at 80 mg·kg À1 ( Figure 3A ). Additionally, a substantial decrease in tumour volumes was observed in LW106-treated mice relative to vehicle-treated mice ( Figure 3B ). LW106 treatment at 80 mg·kg À1 did not suppress outgrowth of B16F10 tumours that were inoculated in athymic nude mice or Ido1 À/À mice ( Figure 3C, D) , further support the notion that T-cell immunity and IDO1 targeting in the host-derived cells are essential for antitumour efficacy of LW106.
LW106 treatment enhanced the infiltration and accumulation of Tcells in xenografted tumours
Given that T-cell-dependent immunity is essential for tumour-suppressive activity of LW106, we sought to study the effector T cell and regulatory T cell compartments within the Lewis and B16F10 tumours following LW106 treatment. For this purpose, tumours were harvested 18 days after implantation, and tumour-infiltrating lymphocytes were isolated and subjected to FACS analysis. We observed a significantly increased number of tumour-infiltrating CD8 effector T cells (CD8 + CD45 + ) in mice treated with LW106 as compared with vehicle-treated mice ( Figure 4A ; Figure S6A ). LW106 treatment also increased infiltration of proliferative CD8 effector T cells within the xenografted tumours, as measured by expression of Ki67, a widely used cell proliferating marker ( Figure 4B ). By contrast, infiltration of regulatory T cells (CD4 + Foxp3 + CD45 + ) was robustly reduced in LW106-treated mice relative to vehicle-treated mice ( Figure 4C ). A dramatic decrease in the percentage of proliferative regulatory T cells was observed within xenografted tumours of LW106-treated mice ( Figure 4D ; Figure S6B ). Intratumoural ratios of CD4 effector T cells (CD4 + Foxp3 À CD45 + ) to regulatory T cells were markedly elevated in LW106-treated mice as compared with vehicle-treated mice ( Figure 4E ; Figure  S6C ). Additionally, immunofluorescence analysis further revealed a robustly increased infiltration of proliferative CD8 effector T cells (Ki67 + CD8 + ) within xenografted tumours of LW106-treated mice ( Figure 4F ; Figure S6D ).
LW106 treatment enhanced accumulation of splenic Tcells in Lewis tumour-bearing mice
Because spleen serves as an important reservoir for lymphocytes that can be recruited to the tumour sites and directly involve in antitumour immunity, we therefore sought to study the effector T cell and regulatory T cell compartments in the spleens of tumour-bearing mice. We observed markedly (n = 5 mice, each). Statistical significance was evaluated by two-way ANOVA test (A, B, C, E and F; *P < 0.05; # P < 0.05) and Log-Rank test (D).
enlarged spleens in mice that received LW106 treatment as compared with epacadostat-or vehicle-treated mice ( Figure 5A, B) . Importantly, H&E staining of spleens from LW106-treated mice revealed no distinguished pathological changes ( Figure 5C ). Flow cytometry analysis of splenocytes revealed a higher percentage of CD8 effector T cells in the spleens of LW106-treated mice as compared to vehicletreated mice ( Figure 5D ). Furthermore, LW106 treatment significantly increased the percentage of proliferative CD8 and CD4 effector T cells in tandem with a marked reduction in the percentage of proliferative regulatory T cells in the spleens (Figure 5E -G). Taken together, these results suggest that LW106 treatment increased the number of splenic effector T cells that can be recruited to the tumour sites and function there.
LW106 treatment resulted in impaired proliferation and survival of tumour cells in tandem with reduced recruitment of non-haemopoietic stromal cells and deposition of ECM in the TME
The data above had shown that tumour outgrowth was significantly inhibited in LW106-treated mice. We next Targeting IDO1 limits stroma-immune crosstalk Targeting IDO1 limits stroma-immune crosstalk and α-SMA (rest rows at right panels; relative fluorescent intensities were calculated in 10 random fields of each slide) for tumours of indicated mice (n = 6 mice, each). Statistical significance was evaluated by two-way ANOVA test (*P < 0.05; # P < 0.05; N.S., not significant).
sought to determine whether LW106 treatment could affect the proliferation and survival of tumour cells within Lewis and B16F10 tumours. For this purpose, we performed immunohistochemical staining of Ki67 (a proliferative cell marker), phospho-Histone H3 (a mitotic cell marker) and cleaved caspase 3 (an apoptotic cell marker) in the xenografted tumours. We found that the percentages of proliferative and mitotic cells were markedly decreased in tumours of LW106-treated mice relative to vehicle-treated mice ( Figure 6A ; Figure S7A ). By contrast, the percentage of apoptotic cells was significantly increased in tumours of LW106-treated mice ( Figure 6A ; Figure S7A ). A reduced number of cytokeratin-14 (K14)-positive tumour cells (i.e. invasive tumour cells) was also observed in tumours of LW106-treated mice ( Figure 6B ). These data suggest that LW106 treatment decreases the proliferation, survival and invasiveness of tumour cells, thus suppressing tumour outgrowth.
The relationship between the stroma and tumourinfiltrating lymphocytes remains largely uncharacterized (Turley et al., 2015) . Emerging evidences have suggested that the stromal compartments (e.g. CAFs, ECs as well as ECM) can shape antitumour immunity and responsiveness to immunotherapy (Turley et al., 2015) . We therefore sought to determine whether LW106 treatment could affect the recruitment of non-haematopoietic stromal cells and the deposition of stroma-derived ECM in the TME, which may contribute to its antitumour effect. Immunohistochemical assay showed that type I collagen expression level was significantly decreased in tumours of LW106-treated mice, indicating a reduced ECM deposition in the tumours following LW106 treatment ( Figure 6B ; Figure  S7B ). We further observed that the percentages of CD31-positive cells (i.e. ECs) and α-SMA-positive cells (i.e. CAFs) were substantially reduced in tumours of LW106-treated mice as compared with vehicle-treated mice ( Figure 6B ; Figure S7B ). These data illustrated that targeting IDO1 in host-derived cells by LW106 inhibited recruitment of non-haematopoietic stromal cells and deposition of ECM, which could generate a tumour-suppressive microenvironment within the tumours and thus suppress tumour outgrowth.
LW106 treatment inhibited enrichment of CSCs in xenografted tumours
CSCs, a population tumour cells that possess the defining features of clonogenicity and self-renewal, are proposed to have a critical role in tumour progression, metastasis and drug resistance (Codony-Servat et al., 2016; Hardavella et al., 2016; Ni et al., 2016) . CSCs in human lung tumours were identified using a list of markers such as CD133, CD44 and ALDH1 (Codony-Servat et al., 2016; Hardavella et al., 2016) . To test whether these markers could also be used for identification of CSCs in Lewis xenografted tumours, we sorted tumour cells using FACS with these markers and performed in vitro tumoursphere assays. Although we could not detect CD133 expression in the xenografted tumours (data not shown), we indeed observed that ALDH + or CD44 + ALDH + cells possessed the potentials to form tumoursphere ( Figure 7A ). These results suggest that both CD44 and ALDH1 can be used as markers for identification of CSCs in Lewis xenografted tumours. We further found that xenografted tumours of LW106-treated mice displayed markedly reduced numbers of CD44 + , ALDH + or CD44 + ALDH + cells as compared with vehicle-treated mice ( Figure 7B ), which may be attributed to the regression of tumours observed in LW106-treated mice ( Figure 2A ).
Discussion
Inhibition of IDO1 is a very promising area of cancer immunotherapy. Three small-molecule inhibitors of IDO1, 1-MT, NLG919 and epacadostat, are currently in clinical trials for treatment of various types of cancer including NSCLC, ovarian cancer and melanoma (Cady and Sono, 1991; Liu et al., 2010; Jackson et al., 2013) . These compounds possess potential immunomodulating and antineoplastic activities by inhibiting IDO1 enzyme activity in the tumour cells and host-derived immune cells such as DCs and macrophages (Cady and Sono, 1991; Liu et al., 2010; Jackson et al., 2013) .
In the present study, we have discovered LW106 as a structurally novel, selective and potent small-molecule inhibitor of IDO1. In comparison with epacadostat, LW106 showed a weaker in vitro inhibition on IDO1 enzyme activity when assayed in IFN-γ-stimulated HeLa cells but indeed displayed a stronger antitumour efficacy in mice bearing xenografted tumours. It is unlikely that the antitumour activity of LW106 is due to the 'off-target' effect as the compound does not suppress tumour outgrowth in Ido1 À/À mice. A possible explanation for the distinguished inhibition performed by LW106 in vitro versus in vivo is that LW106 might be metabolized into potential metabolite(s) in vivo that can inhibit IDO1 enzyme activity more efficiently than LW106 itself, and further work is required to identify and synthesize the potential metabolite(s) and evaluate their antitumour efficacy. Nevertheless, LW106 can be considered as a potent and selective inhibitor of IDO1 since treatment with the compound causes a strong tumour regression in IDO1-intact mice but fails to inhibit tumour outgrowth in IDO1-deficient mice. Inhibition of IDO1 enzyme activity in tumour cells appears not to affect cell growth in vitro as tumour cells grow normally when treated with LW106 at a concentration of over 100-fold higher than EC 50 . The inhibitory effect of LW106 on tumour outgrowth in vivo is related to IDO1 expression by host-derived immune cells but not tumour cells since LW106 administrated in vivo display a comparable inhibitory effect on proliferation of IDO1-expressing xenografts versus IDO1-nonexpressing xenografts. In addition, Kaplan-Meier survival analysis reveals that the mRNA levels of IDO1 expressed by tumour cells do not correlate with the survivals in patients with various types of cancers such as lung, ovarian, breast or gastric cancer. Hence, it is reasonable to propose that IDO1 expression by host-derived cells rather than tumour cells can be used as a predictive marker for response to therapy with LW106 as well as other selective inhibitors of IDO1 such as NLG919 (Jackson et al., 2013) and epacadostat (Liu et al., 2010) and that such immunotherapy can also be beneficial for patients with undetectable IDO1 expression in tumour cells.
Emerging evidence suggests that the stromal compartment in the TME may hinder antitumour immune response via actively interacting with the surrounding immune cells (Joyce and Pollard, 2009; Turley et al., 2015) . For instance, non-haematopoietic stromal cells such as CAFs and ECs express numerous surface and secreted molecules to directly suppress CD4 + and CD8 + effector T cells and activate suppressive myeloid cells and CD4 + regulatory T cells (Castermans and Griffioen, 2007; Buckanovich et al., 2008; Joyce and Pollard, 2009; Tan et al., 2011; Feig et al., 2013) . The stroma- stem cells for tumours of indicated mice (right panels; n = 6 mice in three pools). Statistical significance was evaluated by two-way ANOVA test (*P < 0.05; # P < 0.05).
derived ECM in the TME may also suppress antitumour immune response by limiting T cell motility and localization (Joyce and Pollard, 2009; Provenzano et al., 2012; Salmon et al., 2012; Caruana et al., 2015) . Of note, immune cells including regulatory T cells, cancer-associated macrophages (CAMs; F4/80 + cells) and suppressive myeloid cells also secrete numerous molecules, to directly support activation and survival of stromal cells (Joyce and Pollard, 2009; Beatty et al., 2011; Lu et al., 2011; Coussens et al., 2013; Turley et al., 2015) . In the current study, we have discovered that LW106 profoundly inhibits stromal cell recruitment and ECM deposition in the TME, which in turn causes an impaired crosstalk between stromal compartment and T cells, thus promoting T cell immune response to tumours. On the other hand, our data suggest that targeting IDO1 in hostderived cells by LW106 strongly suppresses infiltration of CD4 + Foxp3 + regulatory T cells and F4/80 + CAMs (data not shown), which consequently results in an impaired immune-stroma interaction, thus limiting recruitment, activation and survival of stromal cells in the TME. Further work is required to define the precise mechanisms by which LW106 inhibits recruitment, activation and survival of nonhaematopoietic stromal cells in the TME. In addition to the immunomodulatory role, stromal compartment in the TME may also have a critical role in controlling CSC expansion (Buckanovich et al., 2008; Joyce and Pollard, 2009) . Herein, we demonstrate that the expansion of CSCs is strongly suppressed in tumours of LW106-treated mice, suggesting that the inhibitory effect of LW106 on tumour growth and chemoresistance can, at least in part, be attributed to reduced CSC enrichment in the TME.
In conclusion, the data presented here suggest that LW106 inhibits tumour growth by limiting stroma-immune crosstalk and CSC enrichment in the TME and that LW106 can be further developed as a potential immunotherapeutic agent used in combination with immune checkpoint inhibitors and (or) chemotherapeutic drugs for cancer treatment. 
Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Figure S4 LW106 treatment reverses CD8+ T-cell suppression mediated by IDO1+ mature DCs. IDO1-immature DCs were treated with 50 ng/ml hIFN-γ and 1 μg/ml LPS for 2 days, and the obtained IDO1+ mature DCs or IDO1-immature DCs were cocultured with purified lymphocytes in the presence of vehicle, LW106 or epacadostat for additional 2 days. Co-cultured cells were harvested, stained with anti-CD8 antibody and subjected to FACS analysis. (A) Representative plot of FACS analysis. (B) Percentage of CD8+ T cells in the co-culture system as described in A. n = 3 independent experiments. Statistical significance was evaluated by two-way ANOVA test (*P < 0.05; **P < 0.01). were counted in 10 random fields of each slide). Arrow head denotes Ki67 + CD8+ cells. Statistical significance was evaluated by two-way ANOVA test (*P < 0.05; **P < 0.01; #P < 0.05; N.S., not significant). Figure S7 LW106 treatment results in impaired proliferation and survival of B16F10 melanoma cells in tandem with reduced recruitment of tumor-associated stromal cells and deposition of extracellular matrix. B16F10 xenografted tumors from vehicle-, LW106-and epacadostat-treated mice were harvested 18 days after tumor challenge and analyzed by immunohistochemistry. (A) Representative immunohistochemical images (left panels; images are representative of images from six mice) and percentages of Ki67-, phospho-histone H3-and cleaved caspase 3-positive cells for tumors of indicated mice (right panels; 1000~2000 cells were counted in 10 random fields of each slide). (B) Representative immunofluorescent images (left panels; images are representative of images from six mice) and relative fluorescent intensities of type I collagen, CD31 and α-SMA (right panels; relative fluorescent intensities were calculated in 10 random fields of each slide) for tumors of indicated mice (n = 6 mice, each). Statistical significance was evaluated by two-way ANOVA test (*P < 0.05; **P < 0.01; ***P < 0.001; N.S., not significant).
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